Results 1 to 10 of about 36,802 (283)
Approach to MPN Symptom Assessment
Current Hematologic Malignancy Reports, 2017 Myeloproliferative neoplasms (MPNs) are recognized for their debilitating symptom burdens. The purpose of this review is to understand the complexity of the MPN symptom burden and identify how validated MPN Patient Reported Outcome (PRO) tools may be integrated into clinical practice to assess the MPN symptom burden.Significant heterogeneity exists ...
Ruben Mesa, Holly Geyer
exaly +4 more sources
Hematology, Transfusion and Cell TherapyThe 2022 updated 5th edition of the World Health Organization Classification of myeloproliferative neoplasms and mastocytosis focused on changes in the rationale behind the classification, combined morphologic, immunophenotypic, molecular, and ...
Haifa Kathrin Al-Ali
doaj +2 more sources
Novel Therapies in Myeloproliferative Neoplasms: Beyond JAK Inhibitor Monotherapy [PDF]
Journal of Immunotherapy and Precision Oncology, 2021 Myeloproliferative neoplasms (MPNs) are clonal hematopoietic disorders that consist classically of polycythemia vera (PV), essential thrombocythemia (ET), and myelofibrosis (MF).
Sophia S. Lee +2 more
doaj +1 more source
Antibiotics, 2021 Healthcare workers’ (HCW) clothing has been shown to harbor multidrug-resistant bacteria (MDRB) and may contribute to transmission. The aim of this study was to evaluate presence of MDRB on HCW uniforms in Cyprus.
Pavlina Lena +6 more
doaj +1 more source
Genomics of MPN progression [PDF]
Hematology, 2020 Abstract The Philadelphia chromosome–negative (Ph−) myeloproliferative neoplasms (MPNs) are a heterogenous group of hematopoietic stem cell diseases characterized by activated JAK/STAT signaling and a variable propensity toward myelofibrotic and leukemic transformation.
Anand A, Patel, Olatoyosi, Odenike
openaire +2 more sources
Passer Journal, 2021 This study was designed to determine the extent of contamination of water storage tanks by non-lactose fermenter Enterobacter spp, and to characterize the chlorine and antibiotic resistance status.
Hastyar H. Najmuldeen
doaj +1 more source
A JAK of all trades: how global phosphoproteomics reveal the Achilles heel of MPNs
Molecular & Cellular Oncology, 2021 While Janus-kinase (JAK)-inhibitors effectively reduce the inflammatory phenotype of myeloproliferative neoplasms (MPN), they do not affect disease burden or presence of the mutated clone to a major extent. Here, we show how Janus-kinase 2 (JAK2)-mutated
Tina M. Schnoeder +2 more
doaj +1 more source
Chronic Myelomonocytic Leukemia: Hematopathology Perspective [PDF]
Journal of Immunotherapy and Precision Oncology, 2021 Our understanding of chronic myelomonocytic leukemia (CMML) has evolved tremendously over the past decade. Large-scale sequencing studies have led to increased insight into the genomic landscape of CMML and clinical implications of these changes. This in
Siba El Hussein +4 more
doaj +1 more source
Assessment of the quality of drinking water of Halabja City-Iraqi Kurdistan [PDF]
Kirkuk Journal of Science, 2015 The quality of drinking water is a crucial factor for human health. The objective of this study was to assess the physicochemical and biological characteristics of the various sources of drinking water in the city of Halabja, Iraqi Kurdistan. Forty water
Attallah O. Kasem +3 more
doaj +1 more source
Applied genomics in MPN presentation [PDF]
Hematology, 2020 Abstract Polycythemia vera, essential thrombocytosis (ET), and primary myelofibrosis (PMF) are grouped together as myeloproliferative neoplasms (MPNs) because of shared clinical, pathologic, and molecular features. The 2005 discovery of the driver mutation JAK2V617F, found in more than 70% of individuals with MPNs and 98% of those with ...
Alison R, Moliterno, Hannah, Kaizer
openaire +2 more sources